Zura Bio Ltd

For the period ended Sep 30, 2026. Filed Oct 27, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Oct 27, 2026

ZURA$1.24-69.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(In thousands, except share and per share data)

	For the Three Months EndedSeptember 30,		For the Nine Months EndedSeptember 30,
	2026	2025	2026	2025
Operating expenses:
Research and development	$19,491	$11,948	$54,943	$31,126
General and administrative	9,282	7,571	28,650	25,709
Total operating expenses	28,773	19,519	83,593	56,835
Loss from operations	(28,773)	(19,519)	(83,593)	(56,835)
Other (income), net
Interest income	(1,759)	(1,526)	(4,998)	(5,060)
Other expense (income), net	32	47	(941)	(300)
Total other (income), net	(1,727)	(1,479)	(5,939)	(5,360)
Loss before income taxes	(27,046)	(18,040)	(77,654)	(51,475)
Income tax benefit	(1,221)	—	(1,302)	—
Net loss	$(25,825)	$(18,040)	$(76,352)	$(51,475)
Accretion of redeemable noncontrolling interest to redemption value	—	(2,828)	—	(2,828)
Adjustment of redeemable noncontrolling interest	—	831	—	831
Net loss attributable to Class A Ordinary Shareholders of Zura	$(25,825)	$(20,037)	$(76,352)	$(53,472)
Net loss per share attributable to Class A Ordinary Shareholders of Zura, basic and diluted	$(0.20)	$(0.21)	$(0.62)	$(0.57)
Weighted-average Class A Ordinary Shares used in computing net loss per share attributable to Class A Ordinary Shareholders of Zura, basic and diluted	127,712,533	94,564,632	122,303,170	93,941,675

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.